TDI Episode 49: Pharma Huckman’s Market

March 23, 2008

Guest: Mike Huckman, CNBC Pharmaceutical Reporter brings great deal of timely information regarding the Pharma and Biotech sectors. We discuss Merck (MRK), Amgen (AMGN), Genentech (DNA), Dendreon (DNDN), Pfizer (PFE) and others.

Mike’s writes a terrific blog and appears daily on CNBC.

Mike Huckman

Andrew discusses the current markets and provides a few strategic moves for profit potential. Last week was a see-saw market and if positioned correctly, your portfolio could be holding up well. Even so, it looks as though the economic environment could continue to deteriorate. In this episode, we explore the next looming problem and how to protect yourself.

**AWARENESS and discussion of the Credit Card Crisis has not yet made it to the mainstream headlines, but we see that there is potential for additional economic fallout as Americans continue to build credit in order to pay for their increasingly expensive lifestyles.**

In this edition of The ZachZone, Visa (V) and upcoming IPOs are discussed.

Newsflashr

(This edition of The ZachZone is sponsored by Newsflashr - Get a wide angle view of all of the hot topics making news - All on a single page. )

~ Listen and Subscribe in iTunes ~

Other Stocks Mentioned in this and recent episodes: (V) (BSC) (LEH) (SPY) (SAFM) (GS) (MER) (QID) (SKF) (QQQQ) (IBKR)

 
icon for podpress  TDI Episode 49: Pharma Huckman's Market [39:29m]: Play Now | Play in Popup

Tags: , , , ,

Related posts

Written by Andrew Horowitz · Filed Under PODCASTS 

Comments

3 Responses to “TDI Episode 49: Pharma Huckman’s Market”

  1. TDI Episode 49: Pharma Huckman’s Market | Pharma Night Fever on March 23rd, 2008 3:29 pm

    [...] Read the rest of this great post here [...]

  2. Christian on March 24th, 2008 11:09 am

    Perhaps you could look into the COI’s of Dr.’s Maha and Scher, a we bit more. Maybe you could let us know what happened w/ Dr. Scher’s Novacea trials in regards to Asentar. I believe it was canceled because of a high rate of deaths. I enjoyed your interview w/ Mr. Huckman. Perhaps a little more insight into frequency of the FDA rejecting its own panel. Especially when the votes are 17-0 and 13-4. I look forward to your follow up story w/regards to Provenge.

  3. Tony F on March 24th, 2008 4:23 pm

    Mike and for those reading on the Provenge debacle who are not up-to-speed about alleged Conflict of Interests attributed to the veneral Dr. Howard Isadore Scher of Sloan-Kettering in NYC–the same person who sat in judgment at the Provenge FDA Advisory Committee meeting almost exactly a year ago… here’s what’s been found on the internet.

    Remember, Scher attested to the FDA in writing that he had but 3 COI… 1 stock and 2 competing company interests…. and, pay particular attention to items #1 and #17!!!!!

    #

    Those 17 Conflicts of Interest for Dr. Howard Isadore Scher found on the internet are:

    [NOTE particularly items #1 and #17]

    1. NOVACEA: grants & research support; STUDY CHAIR of DN-101;

    …. and DIRECT COMPETITOR to Provenge

    2. GPB BIOTECH: financial conflict of interest per Scher in MedPage

    3. PHARMION: financial conflict of interest per Scher in MedPage

    4. SANOFI-AVENTIS: grants & research support

    5. BRISTOL MYERSSQUIBB: consultant, grants & research

    6. MILLENNIUM PHARMCEUTICALS: grant of research support

    7. COUGAR BIOTECHNOLOGY: principal investigator; advisoryboard;

    8. INNOVIVE PHARMACEUTICALS: principal investigator

    9. INFINITY PHARMACEUTICALS: principal investigator

    10. BIOGEN-IDEC: jointly held stock with spouse

    11. PFIZER: jointly held stock with spouse

    12. GENTA: scientific advisory board (as of March 6, 2007; since removed from web but
    cached)

    13. CONFOMA THERAPEUTICS: scientific advisory board

    14. DEPARTMENT of DEFENSE: Principal Investigator PCClinical Trials-P1 and P2

    15. AMBRILIABIOPHARMA INC: Principal Investigator PCK3145, Phase I/II

    16. MEDIVATION, INC: principal investigator MDV3100

    17. PROQUEST INVESTMENTS, Board of Directors, Advisor. Invested in Novacea.

Got something to say?